EP2978417A4 - Composition and method for inducing epo-mediated haemoglobin expression and mitochondrial biogenesis in nonhaematopoietic cell - Google Patents

Composition and method for inducing epo-mediated haemoglobin expression and mitochondrial biogenesis in nonhaematopoietic cell Download PDF

Info

Publication number
EP2978417A4
EP2978417A4 EP13880425.7A EP13880425A EP2978417A4 EP 2978417 A4 EP2978417 A4 EP 2978417A4 EP 13880425 A EP13880425 A EP 13880425A EP 2978417 A4 EP2978417 A4 EP 2978417A4
Authority
EP
European Patent Office
Prior art keywords
mediated
composition
mitochondrial biogenesis
epo
inducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13880425.7A
Other languages
German (de)
French (fr)
Other versions
EP2978417A1 (en
Inventor
Rong-Tsun Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wu Sophia Shu Fen
Original Assignee
Wu Sophia Shu Fen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wu Sophia Shu Fen filed Critical Wu Sophia Shu Fen
Publication of EP2978417A1 publication Critical patent/EP2978417A1/en
Publication of EP2978417A4 publication Critical patent/EP2978417A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP13880425.7A 2013-03-28 2013-03-28 Composition and method for inducing epo-mediated haemoglobin expression and mitochondrial biogenesis in nonhaematopoietic cell Withdrawn EP2978417A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2013/034381 WO2014158165A1 (en) 2013-03-28 2013-03-28 Composition and method for inducing epo-mediated haemoglobin expression and mitochondrial biogenesis in nonhaematopoietic cell

Publications (2)

Publication Number Publication Date
EP2978417A1 EP2978417A1 (en) 2016-02-03
EP2978417A4 true EP2978417A4 (en) 2017-03-01

Family

ID=51624947

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13880425.7A Withdrawn EP2978417A4 (en) 2013-03-28 2013-03-28 Composition and method for inducing epo-mediated haemoglobin expression and mitochondrial biogenesis in nonhaematopoietic cell

Country Status (8)

Country Link
EP (1) EP2978417A4 (en)
JP (1) JP2016516745A (en)
KR (1) KR20150135430A (en)
CN (1) CN105188688A (en)
AU (1) AU2013384234A1 (en)
CA (1) CA2907965C (en)
HK (1) HK1219871A1 (en)
WO (1) WO2014158165A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016201953A1 (en) * 2015-06-16 2016-12-22 Rong-Tsun Wu Method for treating or preventing dry eyes
US10040813B2 (en) * 2015-07-23 2018-08-07 Acahealth Pharma & Biotech Co., Ltd. Compounds as positive allosteric modulators for erythropoietin and erythropoietin receptor to treat erythropoietin deficiency diseases
CN106822160A (en) * 2017-02-16 2017-06-13 中国人民解放军第四军医大学 Application of the Stibene-glucoside in the medicine and health products for preparing obesity-related hypertension
CN107349213A (en) * 2017-07-10 2017-11-17 苏州神瑞生物科技有限公司 Applied based on the synthesising preparation of Stibene-glucoside in treatment nerve degenerative diseases medicine is prepared
CN109999047A (en) * 2019-04-19 2019-07-12 浙江大学 Two-step method screens mitochondrial disease drug
CN113599357B (en) * 2021-07-30 2023-03-24 中国医学科学院生物医学工程研究所 Application of ROS (reactive oxygen species) -responsive nanoparticles coated with hematopoietic growth factors in preparation of drugs for treating hematopoietic injuries

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090324751A1 (en) * 2008-06-13 2009-12-31 Development Center For Biotechnology Chinese herb extract for treating dementia and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1161944B1 (en) * 1999-01-29 2006-09-20 Sunstar Inc. Drugs, foods and oral compositions containing stilbene-type compounds
US20050042314A1 (en) * 2003-08-22 2005-02-24 National Yang-Ming University Extracts of Polygonum multiflorum Thunb., and preparation process and uses of the same
US20100160243A1 (en) * 2008-12-24 2010-06-24 National Yang-Ming University Compounds and methods for enhancing erythropoiesis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090324751A1 (en) * 2008-06-13 2009-12-31 Development Center For Biotechnology Chinese herb extract for treating dementia and preparation method thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LI X ET AL: "Tetrahydroxystilbene glucoside attenuates MPP<+>-induced apoptosis in PC12 cells by inhibiting ROS generation and modulating JNK activation", NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 483, no. 1, 8 October 2010 (2010-10-08), pages 1 - 5, XP027243566, ISSN: 0304-3940, [retrieved on 20100826] *
See also references of WO2014158165A1 *
ZHANG WEI ET AL: "Treatment with 2,3,4',5-tetrahydroxystilbene-2-O-.beta.-D-glucoside in atherosclerosis in rats", ZHONGGUO YAOKE DAXUE XUEBAO - JOURNAL OF CHINA PHARMACEUTICAL UNIVERSITY, NANJING, CN, vol. 38, no. 3, 1 January 2007 (2007-01-01), pages 261 - 264, XP008119057, ISSN: 1000-5048 *

Also Published As

Publication number Publication date
AU2013384234A1 (en) 2015-10-15
HK1219871A1 (en) 2017-04-21
CN105188688A (en) 2015-12-23
CA2907965A1 (en) 2014-10-02
JP2016516745A (en) 2016-06-09
CA2907965C (en) 2021-12-07
WO2014158165A1 (en) 2014-10-02
KR20150135430A (en) 2015-12-02
EP2978417A1 (en) 2016-02-03

Similar Documents

Publication Publication Date Title
EP3068240A4 (en) Theacrine-based supplement and method of use thereof
EP3010405A4 (en) Method and device to measure biosignal
HK1207075A1 (en) Glucopyranosyl derivatives and their uses in medicine
EP3004833A4 (en) Improvements in and relating to tissue sampling
EP3048709A4 (en) Coil-end-molding device and method
EP3091023A4 (en) Additive used in polymer and preparation method thereof
EP2986710A4 (en) Age-modified cells and methods for making age-modified cells
EP3008541A4 (en) Methods and apparatus to provide power to devices
GB201407698D0 (en) Improvements in and relating to ophthalmo-scopes
GB201305822D0 (en) Improvements in and relating to apparatus and methods
EP3060724A4 (en) Improvements in and relating to couplers
HK1219871A1 (en) Composition and method for inducing epo-mediated haemoglobin expression and mitochondrial biogenesis in nonhaematopoietic cell (epo)
GB201305414D0 (en) Method and composition
EP3005874A4 (en) Food-dough cutting method and device
EP3005405A4 (en) Collision cells and methods using them
EP3037097A4 (en) Polyrotaxane and medicinal composition
GB2517145B (en) Improvements in and relating to packaging apparatus
EP2998661A4 (en) Protection device and protection method
EP2993466A4 (en) Electrophoresis method and electrophoresis device
EP3055816A4 (en) Systems and methods for use in marketing
EP3083467A4 (en) System and method for limiting over-voltage in power supply system
HK1219233A1 (en) Meropenem derivatives and uses thereof
EP3036008A4 (en) Compositions comprising vitamin b12 and intrinsic factor and methods of use thereof
EP3017858A4 (en) Absorption method and absorption device
EP3077788A4 (en) Device and method

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150922

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/28 20060101ALI20161013BHEP

Ipc: A61K 31/05 20060101AFI20161013BHEP

Ipc: A61K 31/045 20060101ALI20161013BHEP

Ipc: A61K 31/7034 20060101ALI20161013BHEP

Ipc: A61P 25/16 20060101ALI20161013BHEP

Ipc: A61K 31/70 20060101ALI20161013BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20170131

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/045 20060101ALI20170125BHEP

Ipc: A61P 25/16 20060101ALI20170125BHEP

Ipc: A61K 31/7034 20060101ALI20170125BHEP

Ipc: A61K 31/70 20060101ALI20170125BHEP

Ipc: A61K 31/05 20060101AFI20170125BHEP

Ipc: A61P 25/28 20060101ALI20170125BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1219871

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170829

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1219871

Country of ref document: HK